Locally Advanced Prostate Cancer Treated With Concomitant Radiation and 5-Fluorouracil: Southwest Oncology Group Study 9024

Gregory P Swanson, James Faulkner, Stephen R. Smalley, Mark J. Noble, Ronald L. Stephens, Timothy J. O'Rourke, Geoffrey R. Weiss, Donald P. Quick, Ian M. Thompson, E. David Crawford

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Purpose: Radiation is considered the standard treatment for locally advanced (T3 and T4) prostate cancer but cure with radiation alone is infrequent. Studies have shown that adding androgen ablation improves the results but there is still much room for improvement. We performed a phase II multi-institutional study to explore the feasibility of concomitant chemoradiotherapy. Materials and Methods: Eligible patients had prostate cancer with clinical evidence of invasion through the prostatic capsule or into the seminal vesicles without evidence of nodal or distant metastasis. Prior prostatectomy was not allowed and patients could not be candidates for surgical resection due to medical reasons or refusal of surgery. Radiation consisted of 7,020 cGy in 39 fractions. Continuous infusion 5-fluorouracil at a dose of 200 mg/m2 daily was started on day 1 and continued 7 days weekly until the last day of radiation. Results: All 30 eligible patients were evaluated for toxicity. Diarrhea was the most common toxicity with grade 3 and 4 diarrhea in 2 and 1 patients, respectively. The only other grade 4 toxicity was hemorrhagic cystitis in 1 patient. There was 1 incident each of grade 3 stomatitis, congestive heart failure, edema, proctitis and hematuria. No patient with grade 3 or 4 toxicity required treatment delay. Ten patients (33%) achieved a negative biopsy and 13 (43%) achieved prostate specific antigen less than 1.0 ng/ml. Six patients (20%) achieved a complete response, defined as negative biopsy and prostate specific antigen less than 1.0 (95% CI 8 to 39). Patients without any biopsies or without prostate specific antigen followup were assumed to be nonresponders. Conclusions: Toxicity was acceptable. The modest response rate indicates that better chemotherapy that improves local and systemic failure is necessary to improve the results. This study confirms the feasibility of a combined chemoradiotherapy approach.

Original languageEnglish (US)
Pages (from-to)548-553
Number of pages6
JournalJournal of Urology
Volume176
Issue number2
DOIs
StatePublished - Aug 2006

Fingerprint

Fluorouracil
Prostatic Neoplasms
Radiation
Prostate-Specific Antigen
Chemoradiotherapy
Biopsy
Diarrhea
Proctitis
Stomatitis
Cystitis
Seminal Vesicles
Feasibility Studies
Hematuria
Prostatectomy
Androgens
Capsules
Edema
Heart Failure
Neoplasm Metastasis
Drug Therapy

Keywords

  • chemotherapy
  • fluorouracil
  • prostate
  • prostatic neoplasms
  • radiotherapy

ASJC Scopus subject areas

  • Urology

Cite this

Swanson, G. P., Faulkner, J., Smalley, S. R., Noble, M. J., Stephens, R. L., O'Rourke, T. J., ... Crawford, E. D. (2006). Locally Advanced Prostate Cancer Treated With Concomitant Radiation and 5-Fluorouracil: Southwest Oncology Group Study 9024. Journal of Urology, 176(2), 548-553. https://doi.org/10.1016/j.juro.2006.03.068

Locally Advanced Prostate Cancer Treated With Concomitant Radiation and 5-Fluorouracil : Southwest Oncology Group Study 9024. / Swanson, Gregory P; Faulkner, James; Smalley, Stephen R.; Noble, Mark J.; Stephens, Ronald L.; O'Rourke, Timothy J.; Weiss, Geoffrey R.; Quick, Donald P.; Thompson, Ian M.; Crawford, E. David.

In: Journal of Urology, Vol. 176, No. 2, 08.2006, p. 548-553.

Research output: Contribution to journalArticle

Swanson, GP, Faulkner, J, Smalley, SR, Noble, MJ, Stephens, RL, O'Rourke, TJ, Weiss, GR, Quick, DP, Thompson, IM & Crawford, ED 2006, 'Locally Advanced Prostate Cancer Treated With Concomitant Radiation and 5-Fluorouracil: Southwest Oncology Group Study 9024', Journal of Urology, vol. 176, no. 2, pp. 548-553. https://doi.org/10.1016/j.juro.2006.03.068
Swanson, Gregory P ; Faulkner, James ; Smalley, Stephen R. ; Noble, Mark J. ; Stephens, Ronald L. ; O'Rourke, Timothy J. ; Weiss, Geoffrey R. ; Quick, Donald P. ; Thompson, Ian M. ; Crawford, E. David. / Locally Advanced Prostate Cancer Treated With Concomitant Radiation and 5-Fluorouracil : Southwest Oncology Group Study 9024. In: Journal of Urology. 2006 ; Vol. 176, No. 2. pp. 548-553.
@article{2f77ce7685254d9694f4a188dc39d26f,
title = "Locally Advanced Prostate Cancer Treated With Concomitant Radiation and 5-Fluorouracil: Southwest Oncology Group Study 9024",
abstract = "Purpose: Radiation is considered the standard treatment for locally advanced (T3 and T4) prostate cancer but cure with radiation alone is infrequent. Studies have shown that adding androgen ablation improves the results but there is still much room for improvement. We performed a phase II multi-institutional study to explore the feasibility of concomitant chemoradiotherapy. Materials and Methods: Eligible patients had prostate cancer with clinical evidence of invasion through the prostatic capsule or into the seminal vesicles without evidence of nodal or distant metastasis. Prior prostatectomy was not allowed and patients could not be candidates for surgical resection due to medical reasons or refusal of surgery. Radiation consisted of 7,020 cGy in 39 fractions. Continuous infusion 5-fluorouracil at a dose of 200 mg/m2 daily was started on day 1 and continued 7 days weekly until the last day of radiation. Results: All 30 eligible patients were evaluated for toxicity. Diarrhea was the most common toxicity with grade 3 and 4 diarrhea in 2 and 1 patients, respectively. The only other grade 4 toxicity was hemorrhagic cystitis in 1 patient. There was 1 incident each of grade 3 stomatitis, congestive heart failure, edema, proctitis and hematuria. No patient with grade 3 or 4 toxicity required treatment delay. Ten patients (33{\%}) achieved a negative biopsy and 13 (43{\%}) achieved prostate specific antigen less than 1.0 ng/ml. Six patients (20{\%}) achieved a complete response, defined as negative biopsy and prostate specific antigen less than 1.0 (95{\%} CI 8 to 39). Patients without any biopsies or without prostate specific antigen followup were assumed to be nonresponders. Conclusions: Toxicity was acceptable. The modest response rate indicates that better chemotherapy that improves local and systemic failure is necessary to improve the results. This study confirms the feasibility of a combined chemoradiotherapy approach.",
keywords = "chemotherapy, fluorouracil, prostate, prostatic neoplasms, radiotherapy",
author = "Swanson, {Gregory P} and James Faulkner and Smalley, {Stephen R.} and Noble, {Mark J.} and Stephens, {Ronald L.} and O'Rourke, {Timothy J.} and Weiss, {Geoffrey R.} and Quick, {Donald P.} and Thompson, {Ian M.} and Crawford, {E. David}",
year = "2006",
month = "8",
doi = "10.1016/j.juro.2006.03.068",
language = "English (US)",
volume = "176",
pages = "548--553",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Locally Advanced Prostate Cancer Treated With Concomitant Radiation and 5-Fluorouracil

T2 - Southwest Oncology Group Study 9024

AU - Swanson, Gregory P

AU - Faulkner, James

AU - Smalley, Stephen R.

AU - Noble, Mark J.

AU - Stephens, Ronald L.

AU - O'Rourke, Timothy J.

AU - Weiss, Geoffrey R.

AU - Quick, Donald P.

AU - Thompson, Ian M.

AU - Crawford, E. David

PY - 2006/8

Y1 - 2006/8

N2 - Purpose: Radiation is considered the standard treatment for locally advanced (T3 and T4) prostate cancer but cure with radiation alone is infrequent. Studies have shown that adding androgen ablation improves the results but there is still much room for improvement. We performed a phase II multi-institutional study to explore the feasibility of concomitant chemoradiotherapy. Materials and Methods: Eligible patients had prostate cancer with clinical evidence of invasion through the prostatic capsule or into the seminal vesicles without evidence of nodal or distant metastasis. Prior prostatectomy was not allowed and patients could not be candidates for surgical resection due to medical reasons or refusal of surgery. Radiation consisted of 7,020 cGy in 39 fractions. Continuous infusion 5-fluorouracil at a dose of 200 mg/m2 daily was started on day 1 and continued 7 days weekly until the last day of radiation. Results: All 30 eligible patients were evaluated for toxicity. Diarrhea was the most common toxicity with grade 3 and 4 diarrhea in 2 and 1 patients, respectively. The only other grade 4 toxicity was hemorrhagic cystitis in 1 patient. There was 1 incident each of grade 3 stomatitis, congestive heart failure, edema, proctitis and hematuria. No patient with grade 3 or 4 toxicity required treatment delay. Ten patients (33%) achieved a negative biopsy and 13 (43%) achieved prostate specific antigen less than 1.0 ng/ml. Six patients (20%) achieved a complete response, defined as negative biopsy and prostate specific antigen less than 1.0 (95% CI 8 to 39). Patients without any biopsies or without prostate specific antigen followup were assumed to be nonresponders. Conclusions: Toxicity was acceptable. The modest response rate indicates that better chemotherapy that improves local and systemic failure is necessary to improve the results. This study confirms the feasibility of a combined chemoradiotherapy approach.

AB - Purpose: Radiation is considered the standard treatment for locally advanced (T3 and T4) prostate cancer but cure with radiation alone is infrequent. Studies have shown that adding androgen ablation improves the results but there is still much room for improvement. We performed a phase II multi-institutional study to explore the feasibility of concomitant chemoradiotherapy. Materials and Methods: Eligible patients had prostate cancer with clinical evidence of invasion through the prostatic capsule or into the seminal vesicles without evidence of nodal or distant metastasis. Prior prostatectomy was not allowed and patients could not be candidates for surgical resection due to medical reasons or refusal of surgery. Radiation consisted of 7,020 cGy in 39 fractions. Continuous infusion 5-fluorouracil at a dose of 200 mg/m2 daily was started on day 1 and continued 7 days weekly until the last day of radiation. Results: All 30 eligible patients were evaluated for toxicity. Diarrhea was the most common toxicity with grade 3 and 4 diarrhea in 2 and 1 patients, respectively. The only other grade 4 toxicity was hemorrhagic cystitis in 1 patient. There was 1 incident each of grade 3 stomatitis, congestive heart failure, edema, proctitis and hematuria. No patient with grade 3 or 4 toxicity required treatment delay. Ten patients (33%) achieved a negative biopsy and 13 (43%) achieved prostate specific antigen less than 1.0 ng/ml. Six patients (20%) achieved a complete response, defined as negative biopsy and prostate specific antigen less than 1.0 (95% CI 8 to 39). Patients without any biopsies or without prostate specific antigen followup were assumed to be nonresponders. Conclusions: Toxicity was acceptable. The modest response rate indicates that better chemotherapy that improves local and systemic failure is necessary to improve the results. This study confirms the feasibility of a combined chemoradiotherapy approach.

KW - chemotherapy

KW - fluorouracil

KW - prostate

KW - prostatic neoplasms

KW - radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=33745459180&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745459180&partnerID=8YFLogxK

U2 - 10.1016/j.juro.2006.03.068

DO - 10.1016/j.juro.2006.03.068

M3 - Article

C2 - 16813886

AN - SCOPUS:33745459180

VL - 176

SP - 548

EP - 553

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 2

ER -